Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Böblingen – page 67

944 clinical trials in Böblingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Böblingen at a glance
944
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

944 trials in Böblingen

Open in trial search

Study of Cemiplimab Compared to Placebo After Surgery and Radiation for Patients with High-Risk Skin Squamous Cell Carcinoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study on the Effectiveness and Safety of Cevostamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Medulloblastoma

Not recruiting

Study on Personalized Treatment for Post-Pubertal Patients with Newly Diagnosed Medulloblastoma Using Sonidegib, Cisplatin, Lomustine, and Vincristine

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of Batoclimab for Treating Patients with Active Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Study on the Safety and Tolerability of Teprotumumab for Patients with Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
  • Sponsor:Pharma Mar S.A.

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Hypercholesterolaemia

Not recruiting

Study on Inclisiran and Rosuvastatin for Lowering Cholesterol in Patients with High Cholesterol Levels

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Böblingen

What the registry says about research in the country

01 Neurological Disorders

Groundbreaking research focusing on multiple sclerosis treatments, including studies comparing new therapies like fenebrutinib and frexalimab with established treatments. Several trials are investigating novel approaches for both relapsing and primary progressive forms of MS.

  • Relapsing Multiple Sclerosis
  • Primary Progressive MS
  • Brain Inflammation

Additional studies explore innovative treatments for migraine prevention in patients who haven't responded to conventional therapies.

02 Mental Health Studies

Comprehensive research into major depressive disorder and schizophrenia, evaluating new therapeutic approaches. Trials include testing novel compounds for depression with anhedonia and long-term safety studies for schizophrenia treatments.

  • Depression Treatment
  • Schizophrenia Management
  • ADHD Therapy

Studies also examine new formulations for ADHD treatment in adults, comparing immediate and modified-release medications.

03 Oncology Research

Innovative trials in breast cancer treatment, particularly focusing on HER2-negative and triple-negative variants. Studies evaluate both neoadjuvant and adjuvant therapeutic approaches.

  • Triple-Negative Breast Cancer
  • HER2-Negative Breast Cancer
  • Rectal Cancer

Additional research examines treatment strategies for locally advanced rectal cancer, comparing pre- and post-surgical interventions.

04 Neurodegenerative Conditions

Critical research into Alzheimer's disease and related conditions, with studies focusing on treating associated symptoms like psychosis and agitation in dementia patients.

  • Alzheimer's Psychosis
  • Dementia Management
  • Behavioral Symptoms

These trials aim to improve quality of life for patients with neurodegenerative disorders through targeted symptom management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.